Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Cortronix Biomedical Advancement Technologies Inc.Financial_Report.xls



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q/A
Amendment No. 1

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
 
For the quarterly period ended  November 30, 2012
   
[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to __________

000-53700
Commission File Number
 
Cortronix Biomedical Advancement Technologies Inc.
(Exact name of registrant as specified in its charter)
   
Nevada
98-0515701
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
   
8200 N.W. 41st Street, Suite 145B, Doral, FL
33166
(Address of principal executive offices)
(Zip Code)
 
(786) 859-3585
(Registrant’s  telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 
Yes [X]  No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 
Yes [   ]  No [ X ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
[  ]
Accelerated filer
[  ]
       
Non-accelerated filer
[  ]
Smaller reporting company
[X]
(Do not check if a smaller reporting company)
     
 

 
 

 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 
Yes [  ] No [X]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 
Yes [  ]  No [  ]

APPLICABLE ONLY TO CORPORATE ISSUERS

287,000,000 shares of common stock issued and outstanding as of January 15, 2013
(Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.)

 
 
2

 
 
EXPLANATORY NOTE

The purpose of this Amendment No. 1 on Form 10–Q/A to Cortronix Biomedical Advancement Technologies Inc.’s quarterly report on Form 10–Q for the quarter ended November 30, 2012, filed with the Securities and Exchange Commission on January 22, 2013 (the “Form 10–Q”), is solely to furnish Exhibit 101 to the Form 10–Q in accordance with Rule 405 of Regulation S–T.

No other changes have been made to the Form 10–Q. This Amendment No. 1 speaks as of the original filing date of the Form 10–Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10–Q.

 
3

 

Item 6.  Exhibits
 
EXHIBITS

Number
Description
 
3.1(a)
Articles of Incorporation.
Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.1(b)
Amendment to Articles of Incorporation
Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 9, 2011.
3.1(c)
Amendment to Articles of Incorporation
Incorporated by reference to the Company’s Definitive 14C filed on November 2, 2012
3.2(a)
Bylaws.
Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.2(b)
Amendment to Bylaws
Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 28, 2011.
10.1
Consulting Services and Finders Fee Agreement, dated February 1, 2012
Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.2
Mining Option Agreement, dated February 1, 2012
Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.3
Mutual Release Agreement by and between the Company and David Gibson
Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.4
Form of Promissory Note
Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.5
Acquisition Agreement between the Company and Cortronix dated August 15, 2012
Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
10.6
Assignment Agreement between Yoel Palomino and Cortronix dated August 10, 2012
Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
31.1
Section 302 Certification - Principal Executive Officer
Incorporated by reference to the Company's Form 10-Q  filed with the Securities and Exchange Commission on January 22, 2013
31.2
Section 302 Certification - Principal Financial Officer
Incorporated by reference to the Company's Form 10-Q filed with the Securities and Exchange Commission on January 22, 2013
32.1
Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Incorporated by reference to the Company's Form 10-Q filed with the Securities and Exchange Commission on January 22, 2013
101.INS
XBRL Instance Document
Filed herewith **
101.SCH
XBRL Taxonomy Extension Schema Document
Filed herewith **
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
Filed herewith **
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
Filed herewith **
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
Filed herewith **
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
Filed herewith **

**Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.
 
 
4

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.
       
Date:
April 24, 2013
By:
/s/ Yoel Palomino
   
Name:
Yoel Palomino
   
Title:
Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director
(Principal Executive Officer, Principal Financial and Principal Accounting Officer)
 

 
5